Side-by-side comparison

NVO vs SYK — Side-by-side comparison

SYK screens cheaper on EV/FCF, SYK has the higher ROIC, SYK has grown revenue faster over five years, and SYK has the cleaner balance sheet by net debt / EBITDA.

NVO

Novo Nordisk A S

Price

$44.96

Market cap

$305.8B

Day %

N/A

SYK

Stryker Corp.

Price

$316.48

Market cap

$145.6B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best
NVO
Target
Novo Nordisk A S$305.8BN/AN/AN/AN/AN/AN/AN/AN/A
SYKStryker Corp.$145.6B37.7x33.0x14.5%11.8%17.1%64.0%-0.6xN/A

NVO implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

N/A

FCF yield

N/A

5Y rev CAGR

N/A

SYK implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

33.0x

FCF yield

2.9%

5Y rev CAGR

11.8%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for NVO.

Grade F
0
/ 100

Quality Scorecard

Build-time composite score for SYK.

Grade B
72
/ 100